AtriCure

AtriCure, Inc. engages in the development, manufacture, and sale of devices designed primarily for the surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. Its products include radio frequency (RF) ablation pacing and sensing, cryo, left atrial appendage management, soft tissue dissection, estech surgical instrumentation, and cart configuration. It operates through the following geographical segments: United States, Europe, Asia, and Other International. The company was founded by Michael D. Hooven on October 31, 2000 and is headquartered in Mason, OH.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AtriCure excels in 2022, eyes growth in cardiac surgery market

AtriCure's strong performance in 2022 sets the stage for continued growth and profitability.
Focus on technological advancements and clinical trials to drive future revenue growth.
Addressing challenges like slower adoption and macro pressures with strategic planning.
Positioned for success with a robust product portfolio and international growth prospects.

AtriCure reports robust Q1 earnings, eyes growth amid competition

AtriCure's Q1 2023 performance was strong, with revenue growth and a focus on profitability. Challenges include cash burn and potential competition in the cryoSPHERE market. The company's innovative approach and growth projections offer promising opportunities.

AtriCure posts robust Q2 results, eyes international growth opportunities

AtriCure's Q2 performance showcased strong revenue growth, margin improvement, and strategic acquisitions, positioning the company for continued success.
While challenges like ongoing investments and product optimization exist, opportunities in international markets, acquisitions, and cardiac surgery trends offer avenues for future growth.
The company's focus on clinical trials, long-term market opportunities, and maintaining a strong balance sheet underscores its commitment to innovation and sustainable growth.

AtriCure (ATRC) reports robust Q3 earnings, eyes growth opportunities

AtriCure's strong Q3 performance and positive outlook for full year 2023 demonstrate growth potential across key franchises. Challenges include market transitions impacting pain management growth and the need to adapt to evolving market dynamics. Opportunities lie in new product launches, clinical trials, and market expansion strategies.

AtriCure reports robust Q4 growth, eyes new products and market opportunities

AtriCure's strong financial performance in Q4 2023 and expectations of 15-17% revenue growth in 2024 showcase sustained momentum.
The company's focus on innovation, product adoption, and market opportunities positions it well for future expansion and impact.
Balancing challenges like product development and market dynamics with pricing strength and operational efficiency will be key for continued success.

AtriCure excels in Q1 2024, eyes global impact with innovations

AtriCure's strong start in 2024 driven by revenue and EBITDA growth.
Focus on innovation, clinical trials, and international expansion.
Challenges include product adoption and R&D investment balance.
Opportunities lie in market leadership, new product launches, and global trials.

AtriCure posts strong Q2 results, eyes EU expansion and trial completion

AtriCure's Q2 2024 performance reflects robust revenue growth and positive EBITDA, driven by key franchise expansions and clinical trials.
While facing challenges such as increased operating expenses and a loss per share, the company maintains a focus on innovation and growth opportunities.
Revised full-year guidance and strategic product launches position AtriCure for continued growth and market leadership in the medical device sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AtriCure, Inc. engages in the development, manufacture, and sale of surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. Its products include radio frequency (RF) ablation pacing and sensing, cryo, left atrial appendage management, soft tissue dissection, estech surgical instrumentation, and cart configuration. It operates through the following geographical segments: United States, Europe, Asia, and Other International. The company was founded in 1994 and is headquartered in Mason, OH.

AtriCure, Inc. (ATRC) CEO Mike Carrel on Q3 2019 Results - Earnings Call Transcript

AtriCure's (ATRC) AtriClip devices are currently the most widely implanted left atrial appendage management devices globally.

AtriCure Gains Expanded Labeling for Atriclip, Braces LAA Arm

AtriCure, Inc. (ATRC) CEO Mike Carrel on Q2 2019 Results - Earnings Call Transcript

AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will AtriCure (ATRC) Report Negative Earnings Next Week? What You Should Know

President, CEO, & Director of Atricure Inc (NASDAQ:ATRC) Michael H Carrel (insider trades) sold 25,000 shares of ATRC on 07/10/2019 at an average price of $32 a share.

Atricure Inc (ATRC) President, CEO, & Director Michael H Carrel Sold $800,000 of Shares

AtriCure's (ATRC) CEO Mike Carrel on Q1 2019 Results - Earnings Call Transcript

News for AtriCure Stock (ATRC)